Singapore markets closed

Xenon Pharmaceuticals Inc. (XENE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
37.25-0.79 (-2.08%)
At close: 04:00PM EDT
36.52 -0.73 (-1.96%)
After hours: 04:44PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close38.04
Open37.75
Bid37.23 x 100
Ask37.43 x 100
Day's range36.57 - 37.75
52-week range27.99 - 50.99
Volume269,627
Avg. volume338,357
Market cap2.811B
Beta (5Y monthly)1.23
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

    VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 45th Annual Global Healthcare Conference taking place June 10-13, 2024 in Miami, FL. Fireside Chat Presentation Details: Date:Wednesday, June 12, 2024Time:4:00 pm Eastern TimeWebcast:Register herePresenters:Ian Mortimer, President and Chief Executive OfficerChris Von Seggern, C

  • GlobeNewswire

    Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting

    VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are pleased to present these data from our Phase 2 proof-of-

  • GlobeNewswire

    Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

    Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful “end-of-Phase 2” interactions with FDA in MDD; Phase 3 program on track to initiate in the second half of the year Azetukalner now the international nonproprietary name (INN) and United States adopted name (USAN) for XEN1101 Conference call at 4:30 pm ET today VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nas